(NASDAQ: CRGX) Cargo Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Cargo Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast CRGX's revenue for 2025 to be $229,644,498, with the lowest CRGX revenue forecast at $229,644,498, and the highest CRGX revenue forecast at $229,644,498. On average, 1 Wall Street analysts forecast CRGX's revenue for 2026 to be $474,967,536, with the lowest CRGX revenue forecast at $474,967,536, and the highest CRGX revenue forecast at $474,967,536.
In 2027, CRGX is forecast to generate $10,837,560,222 in revenue, with the lowest revenue forecast at $10,837,560,222 and the highest revenue forecast at $10,837,560,222.